Technical Articles

This article focuses on the core principles and experimental methods of MHC tetramer technology, systematically explaining how the technology overcomes the technical bottleneck of insufficient affinity between TCR and pMHC monomers through multivalent design. It analyzes the operational workflow and core advantages of this technology on the flow cytometry platform and introduces its wide applications in research fields such as tumor immunology, infectious diseases, and autoimmune diseases.

MHC molecules can bind antigenic peptides derived from pathogens and present them to T cells, thereby initiating an immune response. MHC tetramers are a powerful tool designed based on this principle.

The precise demand for detecting tumor neoantigen-specific T cells in the field of tumor immunology research, targeting T cell responses to neoantigens generated by oncogenic mutations, represents the most promising type of immune response for therapeutic potential.

MHC class I molecules are present on the surface of all nucleated cells and function to "present" protein fragments (i.e., antigenic peptides) from inside the cell to the immune system. If the presented peptides are abnormal fragments produced by viruses or cancer cells, they are recognized by CD8+ T cells, triggering a clearance response.

Simply put, an MHC tetramer is an artificially constructed complex molecule consisting of four major histocompatibility complex molecules linked together by a core scaffold. Each MHC molecule is loaded with a specific antigen peptide (a protein fragment that can elicit an immune response).